CDH2 and leukemia: CDH2 is upregulated upon heterologous cell contact of the leukemic cells with iMSC; in contrast, CDH2 knockdown in either leukemia blasts or iMSC disrupts this interaction, impairs blast survival and proliferation, and leads to the downregulation of key oncogenic pathways (e.g., JAK/STAT signaling).